ARS Pharmaceuticals(US:SPRY)2025-11-10 13:30Neffy Sales Performance and Growth - Neffy US quarterly net sales showed strong growth throughout 2025, reaching $7.8 million in Q1, $12.8 million in Q2 (a 1.64x increase), and $31.3 million in Q3 (a 2.45x increase)[6] - ARS Pharmaceuticals anticipates further accelerated US growth with the addition of neffy to commercial formularies of CVS Caremark/Aetna (~23% of Rx) and Prime (~11%) by Spring 2026[8] - Direct-to-consumer (DTC) campaign significantly increased consumer awareness of neffy, with aided consumer awareness rising from 20% in May 2025 to 56% in September 2025, a 2.8x increase[11] Market Expansion and Patient Satisfaction - Approximately 26% of neffy patients are from market expansion segments, including those who have never had a prescription or are lapsed/non-fillers, representing a significant addressable market in the US[19] - Surveys indicate that 95% of neffy users are likely to refill their prescription, compared to 31% to 39% for epinephrine auto-injectors (EAIs)[22] - 87% of neffy users reported a positive impact on their daily and social life[22] Healthcare Professional (HCP) Engagement - The number of HCPs prescribing neffy has grown significantly, from 5,600 in April 2025 to 18,000 in November 2025[16] - ARS Pharmaceuticals has a total direct reach to approximately 20,000 HCPs, representing about 55% of epinephrine prescriptions from all HCPs[17] - 89% of HCPs prescribe neffy when asked by a patient[11] Financial Position - ARS Pharmaceuticals reported total revenue of $32.5 million and a net loss of $51.2 million for Q3 2025[24] - The company had $288.2 million in cash, cash equivalents, and short-term investments as of September 30, 2025[24] - A $100 million debt facility draw in September 2025 provides additional operational flexibility[24]